These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 24861952)

  • 41. Obesity, race, and long-term prostate cancer outcomes.
    Vidal AC; Oyekunle T; Howard LE; De Hoedt AM; Kane CJ; Terris MK; Cooperberg MR; Amling CL; Klaassen Z; Freedland SJ; Aronson WJ
    Cancer; 2020 Aug; 126(16):3733-3741. PubMed ID: 32497282
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Racial inequities in the quality of surgical care among Medicare beneficiaries with localized prostate cancer.
    Nyame YA; Holt SK; Etzioni RD; Gore JL
    Cancer; 2023 May; 129(9):1402-1410. PubMed ID: 36776124
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prostate-specific antigen levels of ≤4 and >4 ng/mL and risk of prostate cancer-specific mortality in men with biopsy Gleason score 9 to 10 prostate cancer.
    Kim DW; Chen MH; Wu J; Huland H; Graefen M; Tilki D; D'Amico AV
    Cancer; 2021 Jul; 127(13):2222-2228. PubMed ID: 34101827
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database.
    Freedland SJ; Vidal AC; Howard LE; Terris MK; Cooperberg MR; Amling CL; Kane CJ; Aronson WJ;
    Cancer; 2017 Nov; 123(21):4199-4206. PubMed ID: 28654204
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging.
    Muralidhar V; Dinh KT; Mahal BA; Ziehr DR; Chen YW; Viswanathan VB; Nezolosky MD; Choueiri TK; Hoffman KE; Hu JC; Sweeney CJ; Trinh QD; Nguyen PL
    Urol Oncol; 2015 Jul; 33(7):330.e19-25. PubMed ID: 25990612
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The impact of PSA and digital rectal examination on the risk of prostate cancer specific mortality in men with a PSA level <2.5 ng/ml.
    Pashtan I; Chen MH; D'Amico AV
    Cancer Epidemiol; 2014 Oct; 38(5):613-8. PubMed ID: 25164550
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Obese African-Americans with prostate cancer (T1c and a prostate-specific antigen, PSA, level of <10 ng/mL) have higher-risk pathological features and a greater risk of PSA recurrence than non-African-Americans.
    Caire AA; Sun L; Polascik TJ; Albala DM; Moul JW
    BJU Int; 2010 Oct; 106(8):1157-60. PubMed ID: 20367635
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Examining initial treatment and survival among men with metastatic prostate cancer: An analysis from the CaPSURE registry.
    Borno HT; Cowan JE; Zhao S; Broering JM; Carroll PR; Ryan CJ
    Urol Oncol; 2020 Oct; 38(10):793.e1-793.e11. PubMed ID: 32782182
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer.
    Mahal BA; Yang DD; Wang NQ; Alshalalfa M; Davicioni E; Choeurng V; Schaeffer EM; Ross AE; Spratt DE; Den RB; Martin NE; Mouw KW; Orio PF; Choueiri TK; Taplin ME; Trinh QD; Feng FY; Nguyen PL
    Eur Urol; 2018 Aug; 74(2):146-154. PubMed ID: 29478736
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Association of Low Socioeconomic Status With Adverse Prostate Cancer Pathology Among African American Men Who Underwent Radical Prostatectomy.
    Weprin SA; Parker DC; Jones JD; Kaplan JR; Giusto LL; Mydlo JH; Yu SS; Lee DI; Eun DD; Reese AC
    Clin Genitourin Cancer; 2019 Oct; 17(5):e1054-e1059. PubMed ID: 31303559
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer.
    Yang DD; Muralidhar V; Mahal BA; Vastola ME; Boldbaatar N; Labe SA; Nezolosky MD; Martin NE; King MT; Mouw KW; Choueiri TK; Trinh QD; Nguyen PL; Orio PF
    Urol Oncol; 2020 Sep; 38(9):735.e9-735.e15. PubMed ID: 32654951
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Active surveillance for intermediate-risk prostate cancer in African American and non-Hispanic White men.
    Courtney PT; Deka R; Kotha NV; Cherry DR; Salans MA; Nelson TJ; Kumar A; Luterstein E; Yip AT; Nalawade V; Parsons JK; Kader AK; Stewart TF; Rose BS
    Cancer; 2021 Dec; 127(23):4403-4412. PubMed ID: 34347291
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lack of Benefit From the Addition of External Beam Radiation Therapy to Brachytherapy for Intermediate- and High-risk Prostate Cancer.
    Yang DD; Muralidhar V; Nguyen PL; Buzurovic I; Martin NE; Mouw KW; Devlin PM; Trinh QD; Orio PF; King MT
    Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):904-911. PubMed ID: 29063853
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risk of lymph node metastases in pathological gleason score≤6 prostate adenocarcinoma: Analysis of institutional and population-based databases.
    Wenger H; Weiner AB; Razmaria A; Paner GP; Eggener SE
    Urol Oncol; 2017 Jan; 35(1):31.e1-31.e6. PubMed ID: 27692833
    [TBL] [Abstract][Full Text] [Related]  

  • 55. African-American Men with Gleason Score 3+3=6 Prostate Cancer Produce Less Prostate Specific Antigen than Caucasian Men: A Potential Impact on Active Surveillance.
    Kryvenko ON; Balise R; Soodana Prakash N; Epstein JI
    J Urol; 2016 Feb; 195(2):301-6. PubMed ID: 26341575
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer.
    Schmid M; Meyer CP; Reznor G; Choueiri TK; Hanske J; Sammon JD; Abdollah F; Chun FK; Kibel AS; Tucker-Seeley RD; Kantoff PW; Lipsitz SR; Menon M; Nguyen PL; Trinh QD
    JAMA Oncol; 2016 Jan; 2(1):85-93. PubMed ID: 26502115
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9?
    Mahal BA; Muralidhar V; Chen YW; Choueiri TK; Hoffman KE; Hu JC; Sweeney CJ; Yu JB; Feng FY; Trinh QD; Nguyen PL
    BJU Int; 2016 Jul; 118(1):95-101. PubMed ID: 26207642
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Trends in the Incidence of Fatal Prostate Cancer in the United States by Race.
    Kelly SP; Rosenberg PS; Anderson WF; Andreotti G; Younes N; Cleary SD; Cook MB
    Eur Urol; 2017 Feb; 71(2):195-201. PubMed ID: 27476048
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Outcomes of Black men with prostate cancer treated with radiation therapy in the Veterans Health Administration.
    McKay RR; Sarkar RR; Kumar A; Einck JP; Garraway IP; Lynch JA; Mundt AJ; Murphy JD; Stewart TF; Yamoah K; Rose BS
    Cancer; 2021 Feb; 127(3):403-411. PubMed ID: 33036065
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Association Between African American Race and Clinical Outcomes in Men Treated for Low-Risk Prostate Cancer With Active Surveillance.
    Deka R; Courtney PT; Parsons JK; Nelson TJ; Nalawade V; Luterstein E; Cherry DR; Simpson DR; Mundt AJ; Murphy JD; D'Amico AV; Kane CJ; Martinez ME; Rose BS
    JAMA; 2020 Nov; 324(17):1747-1754. PubMed ID: 33141207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.